Medicare Enrolled
Dr. David Friedman, MD
Hematology & Oncology · San Antonio, TX
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Friedman from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Friedman?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Friedman
Dr. David Friedman is a hematology & oncology specialist in San Antonio, TX, with 20 years of NPI registration. Based on federal Medicare data, Dr. Friedman performed 54,279 Medicare services across 2,728 unique beneficiaries.
Between the years covered by Open Payments, Dr. Friedman received a total of $10,957 from 64 pharmaceutical and/or device companies across 599 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Friedman is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice
▲ Top 17% volume in TX
$10,957 industry payments
Medicare Practice Summary
Medicare Utilization ↗54,279
Medicare services
Top 17% in TX for hematology & oncology
2,728
Unique beneficiaries
$6
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~2,714 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Darbepoetin injection (Aranesp) for anemia | 22,345 | $2 | $20 |
| Iron infusion (Feraheme) | 11,730 | $0 | $5 |
| Iron sucrose injection (Venofer) | 6,100 | $0 | $2 |
| Contrast dye for imaging (iodine-based) | 3,740 | $0 | $3 |
| Injection, bortezomib, 0.1 mg | 1,645 | $4 | $116 |
| Blood draw (venipuncture) | 1,007 | $8 | $20 |
| Comprehensive metabolic blood panel | 984 | $10 | $64 |
| Complete blood count (CBC) with differential | 896 | $8 | $36 |
| Office visit, established patient (30-39 min) | 768 | $91 | $368 |
| Injection, granisetron hydrochloride, 100 mcg | 540 | $0 | $24 |
| Dexamethasone injection (steroid) | 492 | $0 | $1 |
| Anti-nausea injection (Aloxi/palonosetron) | 380 | $1 | $114 |
| Measurement of immunoglobulin light chains | 242 | $17 | $60 |
| Hospital follow-up visit, high complexity | 231 | $91 | $357 |
| Office visit, established patient (20-29 min) | 229 | $57 | $250 |
| Administration of chemotherapy into vein, 1 hour or less | 199 | $97 | $707 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 175 | $21 | $157 |
| Ferritin level test (iron stores) | 172 | $13 | $60 |
| Iron level test | 171 | $6 | $27 |
| Iron binding capacity test | 171 | $9 | $35 |
| Protein measurement, serum | 139 | $9 | $77 |
| Lactate dehydrogenase (enzyme) level | 138 | $6 | $31 |
| Drug injection, under skin or into muscle | 132 | $10 | $96 |
| Microscopic examination for white blood cells with manual cell count | 125 | $4 | $22 |
| Injection, zoledronic acid, 1 mg | 124 | $7 | $431 |
| Complete blood count (CBC), automated | 123 | $6 | $34 |
| Immunologic analysis technique on serum (immunofixation) | 117 | $11 | $91 |
| Carcinoembryonic antigen (cea) protein level | 106 | $19 | $99 |
| Office visit, established patient, complex (40-54 min) | 95 | $129 | $496 |
| Injection of additional new drug or substance into vein | 85 | $11 | $108 |
| Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 | 84 | $20 | $128 |
| Injection, diphenhydramine hcl, up to 50 mg | 79 | $1 | $7 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 78 | $54 | $211 |
| Administration of chemotherapy into vein, each additional hour | 73 | $21 | $161 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 72 | $47 | $313 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 63 | $23 | $145 |
| Administration of additional new drug or substance into vein, 1 hour or less | 62 | $48 | $344 |
| New patient office visit (45-59 min) | 58 | $120 | $565 |
| Reticulated (young) platelet measurement | 42 | $35 | $143 |
| Hospital follow-up visit, moderate complexity | 40 | $61 | $247 |
| CT scan of abdomen and pelvis with contrast | 31 | $171 | $1,067 |
| Ct scan of chest with contrast | 30 | $40 | $821 |
| Prothrombin time test (blood clotting) | 27 | $4 | $30 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 26 | $14 | $94 |
| Intensity modulated treatment delivery, single or multiple fields/arcs,via narrow spatially and temporally modulated beams, binary, dynamic mlc, per treatment session | 23 | $272 | $2,762 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 22 | $90 | $657 |
| Radiation treatment delivery,3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 11-19 mev | 21 | $169 | $700 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 20 | $1,109 | $4,802 |
| Hospital follow-up visit, low complexity | 15 | $35 | $135 |
| New patient office visit, complex (60-74 min) | 12 | $126 | $709 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
22.1% high complexity
66.7% medium
11.2% routine
Industry Payment Transparency
Open Payments through 2024 ↗$10,957
Total received (2018-2024)
Avg $1,565/year across 7 years
Top 31% in TX for hematology & oncology
64
Companies
599
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$10,663 (97.3%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$294 (2.7%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$1,202
2023
$1,027
2022
$644
2021
$181
2020
$540
2019
$4,402
2018
$2,960
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Novartis Pharmaceuticals Corporation
$1,395
AstraZeneca Pharmaceuticals LP
$1,205
Amgen Inc.
$733
E.R. Squibb & Sons, L.L.C.
$725
Genentech USA, Inc.
$669
Janssen Biotech, Inc.
$431
Merck Sharp & Dohme Corporation
$425
GENZYME CORPORATION
$423
Incyte Corporation
$375
PFIZER INC.
$362
Janssen Pharmaceuticals, Inc
$311
Seattle Genetics, Inc.
$279
Lilly USA, LLC
$252
AbbVie, Inc.
$251
TESARO, Inc.
$187
Astellas Pharma US Inc
$176
Bayer HealthCare Pharmaceuticals Inc.
$174
Celgene Corporation
$167
Takeda Pharmaceuticals U.S.A., Inc.
$166
Gilead Sciences, Inc.
$162
Boehringer Ingelheim Pharmaceuticals, Inc.
$139
Bayer Healthcare Pharmaceuticals Inc.
$137
Genmab U.S., Inc.
$125
G1 Therapeutics, Inc.
$125
Agios Pharmaceuticals, Inc.
$122
Merck Sharp & Dohme LLC
$101
GlaxoSmithKline, LLC.
$98
Daiichi Sankyo Inc.
$78
JAZZ PHARMACEUTICALS INC.
$75
Regeneron Healthcare Solutions, Inc.
$75
Taiho Oncology, Inc.
$65
Jazz Pharmaceuticals Inc.
$63
Alexion Pharmaceuticals, Inc.
$58
Exelixis Inc.
$56
Puma Biotechnology, Inc.
$55
Helsinn Therapeutics (U.S.), Inc.
$54
Ipsen Biopharmaceuticals, Inc
$53
AVEO Pharmaceuticals, Inc.
$50
TerSera Therapeutics LLC
$44
BOSTON SCIENTIFIC CORPORATION
$37
Acrotech Biopharma Inc.
$36
EISAI INC.
$32
EMD Serono, Inc.
$30
Rigel Pharmaceuticals, Inc.
$25
AMAG Pharmaceuticals, Inc.
$25
Kyowa Kirin, Inc.
$25
Ethicon US, LLC
$24
Sandoz Inc.
$23
Spectrum Pharmaceuticals Inc.
$23
Sobi, Inc
$22
ARRAY BIOPHARMA INC
$21
SANOFI-AVENTIS U.S. LLC
$20
Array BioPharma Inc.
$17
Otsuka America Pharmaceutical, Inc.
$16
SOBI, INC
$15
Medtronic USA, Inc.
$15
Alnylam Pharmaceuticals Inc.
$15
Pharmacyclics LLC, An AbbVie Company
$14
Tempus AI, Inc
$14
Clovis Oncology, Inc.
$14
Eisai Inc.
$13
Aveo Pharmaceuticals, Inc.
$13
Siemens Medical Solutions USA, Inc.
$12
Foundation Medicine, Inc.
$12
Top 3 companies account for 30.4% of total payments
Associated products mentioned in payments ›
ABILIFY · ADCETRIS · AFINITOR · AKYNZEO · Abraxane · Alecensa · Aliqopa · Avastin · BALVERSA · BAVENCIO · BELEODAQ · BLENREP · BOSULIF · Balversa · Bavencio · Blincyto · Braftovi · CABLIVI · CABOMETYX · CALQUENCE · COSELA · CYRAMZA · Cabometyx · DARZALEX · DOPTELET · ELITEK · EMEND · EMPLICITI · ENHERTU · ERLEADA · Echelon Flex · Enhertu · Epkinly · Erleada · FARESTON · FERAHEME · FOTIVDA · FOUNDATIONONE · Fabhalta · Folotyn · GAZYVA · GILOTRIF · GIVLAARI · HEMLIBRA · IBRANCE · IMBRUVICA · IMFINZI · IMMULITE Immunoassay Reagents/Test Kit/Clinical Utilization · INJECTAFER · INLYTA · Imbruvica · JADENU · JAKAFI · JEVTANA · KANJINTI · KEYTRUDA · KISQALI · Kyprolis · LIBTAYO · LIBTAYO CEMIPLIMAB-RWLC INJECTION · LYNPARZA · Lenvima · Lonsurf · Lupron Depot · MEKINIST · MVASI · MYLOTARG · NERLYNX · NINLARO · Nerlynx · Neulasta · Nexavar · Nplate · Nubeqa · OJJAARA · OPDIVO · OSTEOCOOL RF ABLATION · PADCEV · PIQRAY · POTELIGEO · PROMACTA · Pomalyst · RYDAPT · Revlimid · Rituxan · Rubraca · SARCLISA · SCEMBLIX · SOMATULINE DEPOT · SPRYCEL · SUTENT · Somatuline Depot · Stivarga · TAGRISSO · TASIGNA · TECENTRIQ · TIBSOVO · Tavalisse · Trodelvy · ULTOMIRIS · VENCLEXTA · VERZENIO · VOTRIENT · VYXEOS · Vectibix · Venclexta · Vitrakvi · WATCHMAN · XARELTO · XGEVA · XOSPATA · XTANDI · Xofigo · ZARXIO · ZEJULA · ZOLADEX · ZYKADIA
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (97%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Equivalent to $20 per 100 Medicare services performed
Geographic Context
Hematology & oncology specialists within 10 mi
56
Per 100K population
2.7
County median income
$70,571
Nearest hospital
SAN ANTONIO BEHAVIORAL HEALTHCARE HOSPITAL
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Friedman is a mixed practice specialist, with above-average Medicare volume (top 17% in TX), with low-engagement industry engagement, with 20 years of NPI registration.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Friedman experienced with darbepoetin injection (aranesp) for anemia?
Based on Medicare claims data, Dr. Friedman performed 22,345 darbepoetin injection (aranesp) for anemia services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Friedman receive payments from pharmaceutical companies?
Yes. Dr. Friedman received a total of $10,957 from 64 companies across 599 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Friedman's costs compare to other hematology & oncology specialists in San Antonio?
Dr. Friedman's average Medicare payment per service is $6. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Friedman) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in San Antonio
Browse hematology & oncology specialists in San Antonio ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in TX
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in TX
Which TX hematology & oncology specialists receive the most from drug and device companies.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
By company
Amgen Inc. Payments to Doctors
See all physicians who received payments from Amgen Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology